For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenues | 819 | 420 | ||
| Cost of revenues | 63 | 42 | ||
| Gross profit | 756 | 378 | ||
| Selling, general and administrative | 12,075 | 11,349 | ||
| Research and development | 862 | - | ||
| Acquired in-process research and development | 1,967 | - | ||
| Research and development | - | 272 | ||
| Loss on impairment of intangible assets | 6,995 | - | ||
| Total operating expenses | 21,899 | 11,621 | ||
| Operating loss | -21,143 | -11,243 | ||
| Interest income | 34 | 81 | ||
| Interest expense-Nonrelated Party | 95 | - | ||
| Interest expense | - | 91 | ||
| Interest expense-Related Party | 186 | - | ||
| Change in fair value of royalties payable due to related parties | 5,709 | -2,239 | ||
| Change in fair value of convertible notes payable | 2 | - | ||
| Loss on debt extinguishment | -3,260 | - | ||
| Net loss on trading debt securities | -564 | - | ||
| Other expenses, net | -2 | -10 | ||
| Total other income (expenses), net | 1,638 | -2,259 | ||
| Loss from operations before income tax provision (benefit) | -19,505 | -13,502 | ||
| Income tax provision (benefit) | -1,810 | 3,141 | ||
| Net loss | -17,695 | - | ||
| Less net loss attributable to non-controlling interest | -512 | - | ||
| Net loss attributable to catheter precision, inc | -17,183 | -16,643 | ||
| Deemed dividend on warrant inducement offer | 0 | 5,158 | ||
| Net loss attributable to catheter precision, inc. common stockholders | -17,183 | -21,801 | ||
| Basic EPS | -15.9 | -6.68 | ||
| Basic Average Shares | 1,080,617 | 3,263,586 | ||
Catheter Precision, Inc. (VTAK)
Catheter Precision, Inc. (VTAK)